Celldex Therapeutics, Inc.

NASDAQ: CLDX
$1.66
-$0.11 (-6.2%)
Closing price March 31, 2020
Here, 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and U.S. Food and Drug Administration (FDA) updates in February and March.
Chris Lange
Ambev, Renren, Celldex, and Yatra Online all posted new 52-week lows Friday.
Paul Ausick
General Electric, Starbucks, General Dynamics, and Celldex all posted new 52-week lows Thursday.
Paul Ausick
Oracle, Starbucks, Helios and Matheson, and Celldex all posted new 52-week lows Wednesday.
Paul Ausick
Banco Bradesco, Gogo, Tesaro, and Celldex all posted new 52-week lows Wednesday.
Paul Ausick
J.C. Penney, Helios and Matheson, Celldex, and Spectra Energy Partners all posted new 52-week lows Tuesday.
Paul Ausick
MGIC Investment Group, Celldex Therapeutics, Juniper Networks, and Healthcare Services Group all posted new 52-week lows on Wednesday.
Paul Ausick
Celldex Therapeutics, Acacia Communications, Apricus Biosciences, and Ctrp.com all posted new 52-week lows Monday.
Paul Ausick
Celldex Therapeutics shares were absolutely crushed on Monday morning after the firm announced results to its midstage breast cancer study.
Chris Lange
Jefferies has compiled a list of over 30 biotech events taking place in 2018 that could result in significant stock moves. Some stocks have the potential to double or even crater, should a study be...
Chris Lange
The top analyst upgrades, downgrades and other research calls include American Airlines, Boeing, Cabot Oil & Gas, Pandora Media, Southern Co. and Vertex Pharmaceuticals.
Jon C. Ogg
Macy's, Tegna, Celldex, and DryShips posted new 52-week lows Tuesday.
Paul Ausick
Celldex Therapeutics was another big mover coming out of the Annual Meeting for the American Society of Clinical Oncology (ASCO). Unfortunately, the move was to the downside.
Chris Lange
24/7 Wall St. has collected several big FDA decisions and mid-stage to late-stage trials that should be announced in October.
Chris Lange
24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in late-September and October.
Chris Lange